Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma Pharmaceutical TechnologyThe FDA has issued a complete response letter to Replimune's biologics license application concerning the RP1 therapy.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA hands another rejection to Replimune’s melanoma therapyNext: Data backs GSK’s ovarian cancer blockbuster hopes Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
